Efficacy of Probiotics in the Gut Microbiota and H Pylori Density
Launched by STATISTICAL CENTER, NTUHCTC · Mar 27, 2016
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
Subjects: Adult subjects aged 20 or greater with moderate to high bacterial load of H. pylori defined as a DOB value greater than 10 will be eligible to this trial. We will screen 150 subjects and it is estimated that 40 H. pylori infected subjects will be eligible. Eligible subjects will be randomized to receive probiotic (Lactobacillus acidophilus and Lactobacillus rhamnosus) or placebo, one pack twice daily, for 28 days. The primary outcome was the reduction in H. pylori load of greater than 20% than baseline. The secondary outcome was the impact of the probiotic on the gut microbiota an...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult subjects aged 20 or greater with moderate to high bacterial load of H. pylori defined as a DOB value greater than 10 will be eligible to this trial
- Exclusion Criteria:
- • history of gastrectomy and colectomy
- • severe underlying illness, such as malignancy, ESRD, liver failure, etc
- • allergy to probiotics
- • symptomatic patients who need PPI, antibiotics, or other probiotics
- • pregnancy and lactating women
- • unable to cooperate with the protocol
About Statistical Center, Ntuhctc
The Statistical Center at NTUH Clinical Trials Center (NTUHCTC) is dedicated to advancing medical research through rigorous statistical analysis and methodology. With a focus on supporting clinical trials, the center provides comprehensive statistical services, including study design, data management, and biostatistical analysis, ensuring robust and reliable results. By collaborating with researchers and healthcare professionals, NTUHCTC aims to enhance the quality of clinical research and contribute to evidence-based medical practices, ultimately improving patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Patients applied
Trial Officials
Jyh-Ming Liou, MD, PhD
Principal Investigator
National Taiwan University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials